These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36934327)

  • 1. Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
    Jongsma MME; Costes LMM; Tindemans I; Cozijnsen MA; Raatgreep RHC; van Pieterson M; Li Y; Escher JC; de Ridder L; Samsom JN
    J Crohns Colitis; 2023 Aug; 17(8):1262-1277. PubMed ID: 36934327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
    Jongsma MME; Vuijk SA; Cozijnsen MA; van Pieterson M; Norbruis OF; Groeneweg M; Wolters VM; van Wering HM; Hojsak I; Kolho KL; van Wijk MP; Teklenburg-Roord STA; de Meij TGJ; Escher JC; de Ridder L
    Eur J Pediatr; 2022 Aug; 181(8):3055-3065. PubMed ID: 35672586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.
    Zhang T; Wang Z; Fan R; Zhang M; Lin Y; Hong L; Zhou X; Hu S; Cheng M; Zhong J
    Biomed Res Int; 2016; 2016():8648307. PubMed ID: 27896276
    [No Abstract]   [Full Text] [Related]  

  • 9. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
    Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
    Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
    PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
    Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study.
    Nones RB; Miranda EF; Marçal GN; Baraúna FDSB; Loures MR; Senger PC; Magro DO; Kotze PG
    Gastroenterol Hepatol; 2024; 47(7):711-720. PubMed ID: 38160706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial.
    Cozijnsen MA; van Pieterson M; Samsom JN; Escher JC; de Ridder L
    BMJ Open Gastroenterol; 2016; 3(1):e000123. PubMed ID: 28090335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.